Long-term safety, tolerability and efficacy of aclidinium bromide in Patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) - LAS-MD-35

Exclusion Criteria

• - Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit
• - Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1
• - Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness
• - History or presence of asthma verified from medical records
• - Chronic use of oxygen therapy greater than or equal to 15 hours per day
• - Patient with uncontrolled infection due to HIV and/or active hepatitis
• - Patients with a history of hypersensitivity reaction to inhaled anticholinergics
• - Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.